Evidence map›Paper›PMID 36830081›Full record

ArticleAntioxidants (Basel, Switzerland)2023

In Vitro Antiglycation Potential of Erva-Baleeira (

Winner Duque Rodrigues, Felipe Nunes Cardoso, Amanda Martins Baviera, André Gonzaga Dos Santos

Open access · goldAbstract read
In one paragraph

Article in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Citric Pectin-Foods (Basel, Switzerland) · 2026
    Article
  2. Molecules (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Unlocking the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Winner Duque RodriguesDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil.ORCID 0000-0001-7760-7060
Felipe Nunes CardosoDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil.
Amanda Martins BavieraDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil.ORCID 0000-0003-0987-5295
André Gonzaga Dos SantosDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, São Paulo State University, Araraquara 14800-903, Brazil.
Universidade Estadual Paulista (Unesp) · BR

Funding

National Council for Scientific and Technological Development GM 131110/2020-9National Institute of Science and Technology on Biodiversity and Natural Products 465637/2014-0
6 · The paper itself

Abstract

background

methodsThe compounds brickellin and cordialin A were obtained by chromatographic methods and identified by spectrometric techniques. Analysis of fluorescent AGEs, biomarkers of amino acid residue oxidation, protein carbonyl groups and crosslink formation were performed in samples obtained from an in vitro model system of protein glycation with methylglyoxal.

resultsEEVc, brickellin and cordialin A significantly reduced the in vitro formation of AGEs, and reduced the damage caused by oxidative damage to the protein.

conclusionsAccording to the results, EEVc, brickellin and cordialin A are potential candidates against AGEs formation, which opens the way to expand the therapeutic arsenal for many pathologies resulting from glycoxidative stress.

Indexed as

antiglycation activitybrickellincordialin ACordia verbenaceaoxidative stress

Identifiers

PMID36830081
PMCPMC9952575
OpenAlexW4321372555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.